Northwest Biotherapeutics Secures $5M Convertible Note and $50M Facility
January 3, 2025
Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it entered into a $5 million convertible Promissory Note